Last reviewed · How we verify
Locally Directed Therapy
Locally directed therapy delivers therapeutic agents directly to tumor sites to maximize local drug concentration while minimizing systemic exposure.
Locally directed therapy delivers therapeutic agents directly to tumor sites to maximize local drug concentration while minimizing systemic exposure. Used for Solid tumors amenable to local administration (specific indications vary by formulation and trial design).
At a glance
| Generic name | Locally Directed Therapy |
|---|---|
| Sponsor | National Cancer Institute (NCI) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach involves administering drugs, biologics, or other therapeutic modalities directly into or adjacent to tumors, allowing high local concentrations at the disease site while reducing systemic toxicity. The strategy can encompass intratumoral injection, regional perfusion, or other localized delivery methods designed to enhance efficacy and tolerability compared to systemic administration.
Approved indications
- Solid tumors amenable to local administration (specific indications vary by formulation and trial design)
Common side effects
- Local injection site reactions
- Tumor-related pain or inflammation
- Systemic adverse events (variable by agent)
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) (NA)
- Study of DF1001 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy (NA)
- Neoadjuvant Tebentafusp for Uveal Melanoma (PHASE2)
- Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) (PHASE3)
- Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.
- A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Locally Directed Therapy CI brief — competitive landscape report
- Locally Directed Therapy updates RSS · CI watch RSS
- National Cancer Institute (NCI) portfolio CI